What is the most recent earnings date for RETA stock?
REATA PHARMACEUTICALS INC-A (RETA) last reported earnings on 8/8/2023.
NASDAQ:RETA • US75615P1030
Past quarterly earnings results for REATA PHARMACEUTICALS INC-A (RETA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2023 | 4.65 | -2.93 | 258.50% | 330.20% | 22.746M | 120.87K | 18,718.57% | 2,885.04% |
| Q1 2023 | -3.14 | -2.47 | -27.16% | -54.68% | 195K | 161.415K | 20.81% | -78.67% |
| Q4 2022 | -2.33 | -2.25 | -3.37% | 0.85% | 501.259K | -100.00% | -100.00% | |
| Q3 2022 | -2.16 | -2.23 | 2.92% | -9.64% | 540K | 658.155K | -17.95% | -92.69% |
| Q2 2022 | -2.02 | -2.06 | 2.03% | -1.00% | 762K | 1.487M | -48.76% | -65.69% |
| Q1 2022 | -2.03 | -2.22 | 8.37% | -9.14% | 914K | 1.584M | -42.30% | -2.77% |
| Q4 2021 | -2.35 | -2.35 | 0.17% | -23.68% | 933K | 1.659M | -43.76% | -70.75% |
| Q3 2021 | -1.97 | -2.21 | 10.79% | -1.55% | 7.391M | 2.116M | 249.29% | 427.93% |
| Q2 2021 | -2.00 | -2.10 | 4.66% | -19.76% | 2.221M | 1.274M | 74.33% | -27.65% |
| Q1 2021 | -1.86 | -2.14 | 13.03% | -26.53% | 940K | 1.212M | -22.44% | -30.37% |
| Q4 2020 | -1.90 | -2.20 | 13.60% | - | 3.19M | 1.474M | 116.42% | - |
| Q3 2020 | -1.94 | -2.02 | 3.86% | - | 1.4M | 1.301M | 7.61% | - |
| Q2 2020 | -1.67 | -2.89 | 42.29% | - | 3.07M | 1.064M | 188.53% | - |
| Q1 2020 | -1.47 | -2.02 | 27.09% | - | 1.35M | 2.083M | -35.19% | - |
Notes
REATA PHARMACEUTICALS INC-A (RETA) last reported earnings on 8/8/2023.
REATA PHARMACEUTICALS INC-A (RETA) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, REATA PHARMACEUTICALS INC-A (RETA) has beaten EPS estimates in 2 out of 4 releases.